Pradhan, Jaya Prakash and Alakshendra, Abhinav (2006): Overseas Acquisition versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?
Download (1MB) | Preview
Very recently overseas acquisition and outward greenfield foreign investment have emerged as the two important modes of internationalization of the Indian pharmaceutical enterprises. This study examines the relative strengths and weaknesses of these strategies so as to suggest which between the two is a more effective internationalization strategy for the Indian pharmaceutical firms, given the nature of their ownership advantages. This analysis has been conducted in three stages. First, the nternationalization process of the Indian pharmaceutical industry has been embedded into a four stage theory emphasizing on the emergence of different modes of internationalization like inward foreign investment, imports, exports, outward greenfield investment, overseas acquisition and contract manufacturing including inter-firm strategic alliances. Second, theoretical perspectives have been developed with regard to the different ways in which greenfield investment and overseas acquisition can maximize the revenue productivity of pharmaceutical firms’ competitive advantages and/or to strengthen their competitive position. Third, case study of Ranbaxy Laboratories has been undertaken to empirically assess its experience with overseas acquisitions. The analysis indicates that the growth and internationalization of Indian pharmaceutical enterprises was critically dependent upon strategic government policies pursued in the past. The Indian experience offers a number of policy lessons to other developing countries wanting to build their domestic base in the pharmaceutical sector. Theoretical understandings indicate that acquisition is a more effective internationalization strategy than greenfield investment since the former not only provides all the benefits that the latter gives, but also several other competitive advantages important for firms’ performance in world market. The experience of Ranbaxy shows that overseas acquisitions have augmented its intangible asset bundle including distribution and market networks and have provided access to an existing market.
|Item Type:||MPRA Paper|
|Original Title:||Overseas Acquisition versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?|
|Keywords:||Indian Pharmaceutical Industry; Foreign Investment; M&As; Trade; Strategic Alliances|
|Subjects:||L - Industrial Organization > L6 - Industry Studies: Manufacturing > L65 - Chemicals; Rubber; Drugs; Biotechnology
L - Industrial Organization > L2 - Firm Objectives, Organization, and Behavior > L20 - General
G - Financial Economics > G3 - Corporate Finance and Governance > G34 - Mergers; Acquisitions; Restructuring; Corporate Governance
F - International Economics > F1 - Trade > F14 - Empirical Studies of Trade
L - Industrial Organization > L2 - Firm Objectives, Organization, and Behavior > L22 - Firm Organization and Market Structure
|Depositing User:||Jaya Prakash Pradhan|
|Date Deposited:||23. Dec 2008 13:24|
|Last Modified:||14. Feb 2013 06:41|
Business Wire (1995), ‘Ranbaxy acquires Ohm Laboratories’, September 25.
Business Wire (1996), ‘Ohm Laboratories Completes New State-of-the-Art Manufacturing Facility; India's Ranbaxy Laboratories U.S. Arm To Produce Broader Line of Oral Generic Pharmaceuticals’, July 31.
Business World (2004), ‘PHARMA M&AS: What's the big deal?’, June 28.
Caves, R. E. (1971), ‘International corporations: The industrial economics of foreign investment’, Economica, 56: 279–93.
Domai.n-B.Com (2005), ‘Matrix Labs acquires Belgian drug firm Docpharma for $263 m’, June 20
Hindu Business Line (2005), ‘Matrix to acquire Belgian drug firm Docpharma for $263 m’, June 20.
FIRMABIZ.com (2001), ‘Ranbaxy's US subsidiary launches ibuprofen-pseudoephedrine combination product’, October 10.
Hindu Business Line (2001), ‘Ranbaxy arm in marketing tie-up for Advil tablets’, October 11.
Hindu Business Line (2002), ‘Ranbaxy to gain royalty from Bayer for Cipro’, Tuesday, December 17.
Hindu Business Line (2002), ‘Ranbaxy: A dose of US’, Friday, January 11.
Hindu Business Line (2003), ‘Novo Nordisk drops clinical trials on Dr Reddy's molecule’, February 07.
Hindu Business Line (2003), ‘Ranbaxy buys Aventis' generics unit in France’, December 14.
Hindu Business Line (2005), ‘Sun Pharma acquires Hungarian unit of US co’, Thursday, August 11.
Hindu Business Line (2006), ‘Bhai Mohan Singh: Pioneer of pharma’, March 29; Economic Times (2006) ‘Story-teller was the story’, April 12.
Hindu Business Line (2006), ‘Dr Reddy's acquisition includes research centre’, February 18.
Hindu Business Line (2006), ‘Dr Reddy's buys German co Betapharm for Rs 2,250 cr — Biggest overseas acquisition by an Indian pharma co’, February 17.
Hymer, S. (1960), The International Operations of National Firms: A Study of Foreign Direct Investment, doctoral dissertation, MIT, (Published in 1976, MIT Press, Cambridge).
India Infoline (2004), ‘Dr.Reddy’s Research Foundation Pharmacophore 2004 Address by Dr K Anji Reddy, Chairman’, January 17. Available at: http://www.indiainfoline.com /nevi/rere.html
Malaysian Industrial Development Authority (2003), ‘Ranbaxy ups stake in local ops’, March 07.
Pradhan, J.P. (2006), ‘Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies’, ISID Working Paper, 2006/05, New Delhi.
Pradhan, J.P. (2005), ‘Outward Foreign Direct Investment from India: Recent Trends and Patterns’, GIDR Working Paper, No. 153, Gujarat Institute of Development Research, Ahmedabad, India.
Ranbaxy (2005), ‘Ranbaxy Gains Approval to Market Pseudoephedrine Hydrochloride Extended—Release Tablets’, Press Release September 28.
Ranbaxy (2005), ‘Ranbaxy Q1, 05 Global Sales At USD 261 Mn’, Press Release April 28.
Ranbaxy Annual Report 2004.
rediff.com (2004), ‘Ranbaxy is what it is because we took risks’, The Rediff Interview/Malvinder Singh, President, Ranbaxy, November 25. Available at: http://ia.rediff.com/money/2004/nov/25inter.htm